SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A fair growth of 9.43% in the revenue at Rs. 17187.40 millions was reported in the March 2026 quarter as compared to Rs. 15706.40 millions during year-ago period.The Net Profit of the company reported a remarkable increase of 222.63% to Rs. 2430.70  millions  from Rs. 753.40 millions in previous same quarter.OP of the company witnessed a marginal growth to 2999.50 millions from 1838.70 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 17187.40 15706.40 9.43 66513.80 60326.30 10.26 66513.80 60326.30 10.26
Other Income 258.80 132.10 95.91 559.00 478.80 16.75 559.00 478.80 16.75
PBIDT 2999.50 1838.70 63.13 11186.10 9492.70 17.84 11186.10 9492.70 17.84
Interest 194.20 237.10 -18.09 865.10 764.70 13.13 865.10 764.70 13.13
PBDT 2557.70 1601.60 59.70 9651.10 8856.70 8.97 9651.10 8856.70 8.97
Depreciation 823.10 686.00 19.99 3110.00 2770.80 12.24 3110.00 2770.80 12.24
PBT 1734.60 915.60 89.45 6541.10 6085.90 7.48 6541.10 6085.90 7.48
TAX -696.10 162.20 -529.16 136.90 1054.70 -87.02 136.90 1054.70 -87.02
Deferred Tax -1014.50 0.00 0.00 -1014.50 0.00 0.00 -1014.50 0.00 0.00
PAT 2430.70 753.40 222.63 6404.20 5031.20 27.29 6404.20 5031.20 27.29
Equity 393.10 393.10 0.00 393.10 393.10 0.00 393.10 393.10 0.00
PBIDTM(%) 17.45 11.71 49.07 16.82 15.74 6.88 16.82 15.74 6.88

Alembic Pharma Share Price

736.95 1.25 (0.17%)
05-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1783.55
Dr. Reddys Lab 1277.80
Cipla 1400.70
Zydus Lifesciences 1088.90
Lupin 2268.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×